Custom Optimer™ Affinity Reagent Development Service
Aptamer Group is a developer of custom Optimer reagents as antibody mimetics for use as tool affinity reagents, in biomarker discovery, as diagnostic reagents and as therapeutic lead candidates.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Aptamer Group is a developer of custom Optimer reagents as antibody mimetics for use as tool affinity reagents, in biomarker discovery, as diagnostic reagents, and as therapeutic lead candidates. Optimers are optimized aptamers, delivering rapid development with customized binding kinetics, and simple, cost-efficient, scalable manufacture to accelerate your pipeline from discovery and development to commercialization.
Biomarker discovery service
Identifying relevant biomarkers from vast proteomic datasets is a major challenge in drug development. Discover how phenotype-driven discovery simplifies complexity to deliver biomarkers precisely aligned with disease context, tissue specificity, and therapeutic goals. This approach enables faster validation and supports both surface and internal targets, accelerating your path to effective, targeted therapies.
Accelerating your journey to the clinic
Accelerating time-to-clinic is critical for therapeutic and diagnostic success, yet traditional antibody development remains costly and slow. Optimer® binders offer a streamlined alternative, cutting timelines by up to 75%.
Discover how the Optimer® platform enables rapid binder optimization, unlocking novel targets and simplifying development, empowering researchers to reach clinical milestones faster and reduce risk across drug and diagnostic pipelines.
Aptamer Group grants Alphazyme the right to incorporate Optimer into hot-start PCR and NGS product formulations
Non-exclusive OEM license grants worldwide rights for Optimer binder in molecular biology applications
Licensing agreed for Optimer as novel vaccine adjuvant
Successful project delivery of Optimer binders with proven function as vaccine adjuvants
Agreement to explore Optimer vehicles for targeted delivery of siRNA
New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA
Aptamer and Timser deliver first cervical cancer blood test
Optimer binders will be developed for use in a cervical cancer blood test
